Demarcating Therapeutic Interventions in IBS

Authors : Sunil Chaudhry, Sunil Chaudhry

DOI : 10.18231/j.jpbs.2020.010

Volume : 8

Issue : 2

Year : 2020

Page No : 65-75

Irritable bowel syndrome (IBS), also referred to as mucus colitis, nervous colon, and spastic colitis is a long-term chronic gastrointestinal disorder that can cause continuous discomfort. IBS has a significant impact on patients’ quality of life due to physical suffering, psychological co-morbidity, social disability and economic non-productivity. It is more common in females and in lower socioeconomic groups. The diagnosis declines with age (with most affected individuals younger than age 50) The diagnosis of IBS relies on a symptom-based classification system known as Rome criteria. The low FODMAP diet is recommended for patients with digestive disorders like Irritable Bowel Syndrome. Current therapy of IBS focuses on the major symptoms experienced by patients. The novel approach in the treatment of IBS is based either on targeting specific receptors in the gastrointestinal tract that are known to be involved in the pathogenesis of the disease.

Keywords: Irritable bowel syndrome (IBS), Bloating, Rome Criteria, FODMAP, 5HTagonists and antogonists.


Citation Data